Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab
The Korean Journal of Internal Medicine
; : 156-160, 2008.
Article
在 En
| WPRIM
| ID: wpr-181611
Responsible library:
WPRO
ABSTRACT
Glycoprotein (GP) IIb/IIIa inhibitors, such as abciximab, are used as adjunctive therapy for percutaneous coronary intervention (PCI) in high-risk non-ST-elevation myocardial infarction (NSTEMI) and in ST-elevation myocardial infarction (STEMI), although their effects when used for STEMI are less clear. As the use of GP IIb/IIIa inhibitors becomes more widespread, determining the risks associated with them becomes more important. The major risks associated with the use of GP IIb/IIIa inhibitors are the potential for major bleeding and thrombocytopenia. This is the first reported case in Korea of hemorrhagic pericarditis resulting in cardiac tamponade associated with the use of abciximab, a commonly used GP Ilb/IIa inhibitor, following PCI.
Key words
全文:
1
索引:
WPRIM
主要主题:
Pericarditis
/
Immunoglobulin Fab Fragments
/
Platelet Aggregation Inhibitors
/
Cardiac Tamponade
/
Angioplasty, Balloon, Coronary
/
Risk Factors
/
Pericardiocentesis
/
Emergency Medical Services
/
Hemorrhage
/
Korea
研究类型:
Etiology_studies
/
Risk_factors_studies
限制:
Aged
/
Humans
/
Male
国家/地区名称主题:
Asia
语言:
En
期刊:
The Korean Journal of Internal Medicine
年:
2008
类型:
Article